Page 1969 - Williams Hematology ( PDFDrive )

1944 Part XII: Hemostasis and Thrombosis Chapter 113: Molecular Biology and Biochemistry of the Coagulation Factors 1945

111. Hayward CP: Multimerin: A bench-to-bedside chronology of a unique platelet and 143. Lamont PA, Ragni MV: Lack of desmopressin (DDAVP) response in men with hemo-
endothelial cell protein—from discovery to function to abnormalities in disease. Clin philia A following liver transplantation. J Thromb Haemost 3:2259–2263, 2005.
Invest Med 20:176–187, 1997. 144. Madeira C, Layman R, de Vera M, et al: Extrahepatic factor VIII production in trans-
112. Nesheim ME, Nichols WL, Cole TL, et al: Isolation and study of an acquired inhibitor plant recipient of hemophilia donor liver. Blood 113:5364–5366, 2009.
of human coagulation factor V. J Clin Invest 77:405–415, 1986. 145. Kumaran V, Benten D, Follenzi A, et al: Transplantation of endothelial cells corrects the
113. Sun H, Yang TL, Yang A, et al: The murine platelet and plasma factor V pools are biosyn- phenotype in hemophilia A mice. J Thromb Haemost 3:2022–2031, 2005.
thetically distinct and sufficient for minimal hemostasis. Blood 102:2856–2861, 2003. 146. Everett L, Cleuren A: Murine coagulation factor VIII is synthesized in endothelial cells.
114. Yang TL, Pipe SW, Yang A, Ginsburg D: Biosynthetic origin and functional significance Blood 123:3697–3706, 2014.
of murine platelet factor V. Blood 102:2851–2855, 2003. 147. Fahs SA, Hille MT, Shi Q, et al: A conditional knockout mouse model reveals endo-
115. Ortel TL, Devore-Carter D, Quinn-Allen M, Kane WH: Deletion analysis of recom- thelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood
binant human factor V. Evidence for a phosphatidylserine binding site in the second 123:3706–3714, 2014.
C-type domain. J Biol Chem 267:4189–4198, 1992. 148. Jacquemin M, Neyrinck A, Hermanns M, et al: FVIII production by human lung
116. Adams TE, Hockin MF, Mann KG, Everse SJ: The crystal structure of activated protein microvascular endothelial cells. Blood 108:515–518, 2006.
C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci U 149. Shahani T, Covens K, Lavend’homme R, et al: Human liver sinusoidal endothelial cells
S A 101:8918–8923, 2004. but not hepatocytes contain factor VIII. J Thromb Haemost 12:36–42, 2014.
117. Peng W, Quinn-Allen Ma, Kane WH: Mutation of hydrophobic residues in the factor 150. Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation fac-
Va C1 and C2 domains blocks membrane-dependent prothrombin activation. J Thromb tor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem
Haemost 3:351–354, 2005. 273:8537–8544, 1998.
118. Stoilova-McPhie S, Parmenter CD, Segers K, et al: Defining the structure of mem- 151. Swaroop M, Moussalli M, Pipe SW, Kaufman RJ: Mutagenesis of a potential immuno-
brane-bound human blood coagulation factor Va. J Thromb Haemost 6:76–82, 2008. globulin-binding protein-binding site enhances secretion of coagulation factor VIII. J
119. Bos MH, Camire RM: A bipartite autoinhibitory region within the B-domain sup- Biol Chem 272:24121–24124, 1997.
presses function in factor V. J Biol Chem 287:26342–26351, 2012. 152. Lenting PJ, Neels JG, van den Berg BM, et al: The light chain of factor VIII com-
120. Bunce MW, Bos MH, Krishnaswamy S, Camire RM: Restoring the procofactor state prises a binding site for low density lipoprotein receptor-related protein. J Biol Chem
of factor Va-like variants by complementation with B-domain peptides. J Biol Chem 274:23734–23739, 1999.
288:30151–30160, 2013. 153. Saenko EL, Yakhyaev AV, Mikhailenko I, et al: Role of the low density lipoprotein-re-
121. Mann KG, Kalafatis M: Factor V: A combination of Dr Jekyll and Mr Hyde. Blood lated protein receptor in mediation of factor VIII catabolism. J Biol Chem 274:37685–
101:20–30, 2003. 37692, 1999.
122. Pittman DD, Tomkinson KN, Michnick D, et al: Posttranslational sulfation of factor 154. Bovenschen N, Rijken DC, Havekes LM, et al: The B domain of coagulation factor VIII
V is required for efficient thrombin cleavage and activation and for full procoagulant interacts with the asialoglycoprotein receptor. J Thromb Haemost 3:1257–1265, 2005.
activity. Biochemistry 33:6952–6959, 1994. 155. Bovenschen N, Mertens K, Hu L, et al: LDL receptor cooperates with LDL recep-
123. Kalafatis M: Identification and partial characterization of factor Va heavy chain kinase tor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood
from human platelets. J Biol Chem 273:8459–8466, 1998. 106:906–912, 2005.
124. Kim SW, Ortel TL, Quinn-Allen MA, et al: Partial glycosylation at asparagine-2181 of 156. Pegon JN, Kurdi M, Casari C, et al: Factor VIII and von Willebrand factor are ligands
the second C-type domain of human factor V modulates assembly of the prothrombi- for the carbohydrate-receptor Siglec-5. Haematologica 97:1855–1863, 2012.
nase complex. Biochemistry 38:11448–11454, 1999. 157. Leyte A, Verbeet MP, Brodniewicz-Proba T, et al: The interaction between human
125. Nicolaes GA, Villoutreix BO, Dahlbäck B: Partial glycosylation of Asn2181 in human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-af-
factor V as a cause of molecular and functional heterogeneity. Modulation of glycosy- finity binding site on factor VIII. Biochem J 257:679–683, 1989.
lation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. 158. Saenko EL, Scandella D: The acidic region of the factor VIII light chain and the C2
Biochemistry 38:13584–13591, 1999. domain together form the high affinity binding site for von Willebrand factor. J Biol
126. Camire RM, Bos MH: The molecular basis of factor V and VIII procofactor activation. Chem 272:18007–18014, 1997.
J Thromb Haemost 7:1951–1961, 2009. 159. Gilbert GE, Kaufman RJ, Arena AA, et al: Four hydrophobic amino acids of the factor
127. Schuijt TJ, Bakhtiari K, Daffre S, et al: Factor Xa activation of factor V is of paramount VIII C2 domain are constituents of both the membrane-binding and von Willebrand
importance in initiating the coagulation system: Lessons from a tick salivary protein. factor-binding motifs. J Biol Chem 277:6374–6381, 2002.
Circulation 128:919–966, 2013. 160. Meems H, Meijer A, Cullinan D, et al: Factor VIII C1 domain residues Lys 2092 and Phe
128. Thorelli E, Kaufman RJ, Dahlback B: Cleavage requirements for activation of factor V 2093 contribute to membrane binding and cofactor activity. Blood 114:3938–3947, 2009.
by factor Xa. Eur J Biochem 247:12–20, 1997. 161. Bloem E, van den Biggelaar M, Wroblewska A, et al: Factor VIII C1 domain spikes
129. Mann KG, Nesheim ME, Church WR, et al: Surface-dependent reactions of the vitamin 2092–2093 and 2158–2159 comprise regions that modulate cofactor function and cel-
K-dependent enzyme complexes. Blood 76:1–16, 1990. lular uptake. J Biol Chem 288:29670–29679, 2013.
130. Mann KG, Hockin MF, Begin KJ, Kalafatis M: Activated protein C cleavage of factor Va 162. Cunningham MA, Pipe SW, Zhang B, et al: LMAN1 is a molecular chaperone for the
leads to dissociation of the A2 domain. J Biol Chem 272:20678–20683, 1997. secretion of coagulation factor VIII. J Thromb Haemost 1:2360–2367, 2003.
131. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V asso- 163. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ: Identification of individual tyrosine
ciated with resistance to activated protein C. Nature 369:64–67, 1994. sulfation sites within factor VIII required for optimal activity and efficient thrombin
132. Duckers C, Simioni P, Spiezia L, et al: Low plasma levels of tissue factor pathway inhib- cleavage. J Biol Chem 269:20095–20102, 1994.
itor in patients with congenital factor V deficiency. Blood 112:3615, 2008. 164. Vehar GA, Keyt B, Eaton D, et al: Structure of human factor VIII. Nature 312:337–342,
133. Vincent L, Tran S: Coagulation factor V A2440G causes east Texas bleeding disorder via 1983.
TFPIα. J Clin Invest 123:3777–3787, 2013. 165. Eaton D, Rodriguez H, Vehar GA: Proteolytic processing of human factor VIII. Correla-
134. Duckers C, Simioni P, Spiezia L, et al: Residual platelet factor V ensures thrombin gen- tion of specific cleavages by thrombin, factor Xa, and activated protein C with activation
eration in patients with severe congenital factor V deficiency and mild bleeding symp- and inactivation of factor VIII coagulant activity. Biochemistry 25:505–512, 1986.
toms. Blood 115:879–886, 2010. 166. Newell JL, Fay PJ: Proteolysis at Arg740 facilitates subsequent bond cleavages during
135. Cripe LD, Moore KD, Kane WH: Structure of the gene for human coagulation factor V. thrombin-catalyzed activation of factor VIII. J Biol Chem 282:25367–25375, 2007.
Biochemistry 31:3777–3785, 1992. 167. Fay PJ, Haidaris PJ, Smudzin TM: Human factor VIIIa subunit structure. Reconstruc-
136. Owren PA: Parahaemophilia; haemorrhagic diathesis due to absence of a previously tion of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem
unknown clotting factor. Lancet 1:446–448, 1947. 266:8957–8962, 1991.
137. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously 168. Lollar P, Parker ET: Structural basis for the decreased procoagulant activity of human
unrecognized mechanism characterized by poor anticoagulant response to activated factor VIII compared to the porcine homolog. J Biol Chem 266:12481–12486, 1991.
protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 169. Fay PJ: Activation of factor VIII and mechanisms of cofactor action. Blood Rev 18:1–15,
90:1004–1008, 1993. 2004.
138. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V asso- 170. Gitschier J, Wood WI, Goralka TM, et al: Characterization of the human factor VIII
ciated with resistance to activated protein C. Nature 369:64–67, 1994. gene. Nature 312:326–330, 1984.
139. Patek AJ, Taylor FH: Hemophilia. II. Some properties of a substance obtained from 171. Kamphuisen PW, Eikenboom JC, Rosendaal FR, et al: High factor VIII antigen levels
normal human plasma effective in accelerating the coagulation of hemophilic blood. J increase the risk of venous thrombosis but are not associated with polymorphisms in
Clin Invest 16:113–124, 1937. the von Willebrand factor and factor VIII gene. Br J Haematol 115:156–158, 2001.
140. Tuddenham EG, Trabold NC, Collins JA, Hoyer LW: The properties of factor VIII 172. Preston AE, Barr A: The plasma concentration of factor VIII in the normal population.
coagulant activity prepared by immunoadsorbent chromatography. J Lab Clin Med 93: II. The effects of age, sex and blood group. Br J Haematol 10:238–245, 1964.
40–53, 1979. 173. Morelli VM, De Visser MC, Vos HL, et al: ABO blood group genotypes and the risk of
141. Shaw E, Giddings JC, Peake IR, Bloom AL: Synthesis of procoagulant factor VIII, factor venous thrombosis: Effect of factor V Leiden. J Thromb Haemost 3:183–185, 2005.
VIII related antigen and other coagulation factors by the isolated perfused rat liver. Br J 174. Fair DS, Marlar RA: Biosynthesis and secretion of factor VII, protein C, protein S, and
Haematol 41:585–596, 1979. the protein C inhibitor from a human hepatoma cell line. Blood 67:64–70, 1986.
142. Bontempo FA, Lewis JH, Gorenc TJ, et al: Liver transplantation in hemophilia A. Blood 175. Fair DS, Marlar RA, Levin EG: Human endothelial cells synthesize protein S. Blood
69:1721–1724, 1987. 67:1168–1171, 1986.

Kaushansky_chapter 113_p1915-1948.indd 1944 9/21/15 2:41 PM